Koo,

Thanks for the correction. Yes, the article does list some companies. Many of those companies develop reagents, antibodies, kits, or technolgies for helping researchers study epigenetics (Illumina, Abcam, Diagnode, ThermoFisher, Qiagen, Sigma-Aldrich, Zymo Research). Additionally, you are right, many of these companies in the list are pharma companies developing small molecule therapeutics in the eptigenetics field: CellCentric, Chroma Therapeutics, Eisai, Novartis, Oncolys, Syndax, Valirx Plc, Merck). However, out of all of these, the only company with any known association with BETinhibitors seems to be Merck. All the other ones are looking at other targets in the epigenetics field (HDAC and EZH2, for example). Here is the info on the Merck/Oncoethix deal that related to BET inhibitors (taken from the latest Zenith PPT):

"Oncoethix was acquired by Merck in January 2015 - $375MM

•Oncoethix only has a single BETi drug, OTX-015

•Limited efficacy in Phase 1 Trials

•It is a Benzodiazepine program which have been hampered by extensive cardiovascular safety in clinical monitoring

•$110MM payment upfront"

The lack of mention of BET inhibitors, as well as lack of mention of RVX, Zenith, Epizyme, Contellation, Roche, Genentech, Tensha, GSK, Bayer, Gilead, BMS, Incyte, Abbvie, suggests that this article doesn't even have BET inhbitors on its radar yet.

Best regards

BearDownAZ